CD40-activated apoptotic tumor cell-pulsed dendritic cell could potentially elicit antitumor immune response: Involvement of Up-regulation of B7-H3 Expression

Journal of Immunotherapy

Volumn 32, Issue 1, 2009, Pages 29-35

  Chen, Cheng ^a   Zhu, Yi Bei ^a   Qu, Qiu Xia ^a   Ge, Yan ^a   Huang, Jian An ^a   Wang, Yong ^a   Zhang, Xue Guang ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

B7 H3; CD40; DCs

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; PROTEIN; PROTEIN B7 H3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; B7 H3 PROTEIN, MOUSE; B7-H3 PROTEIN, MOUSE; CISPLATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; DENDRITIC CELL; FEMALE; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; UPREGULATION; ANIMAL; B CELL LYMPHOMA; BAGG ALBINO MOUSE; DRUG EFFECT; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD40; ANTIGENS, CD80; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DENDRITIC CELLS; FEMALE; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 65549086689     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31818c8816     Document Type: Article

References (27)

1. Banchereau J, Francine B, Christophe C, et al. Immunobiology of dendritic cells.Annu Rev Immunol. 2000;18:767-811.
2. Banchereau J, Steinman R. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
3. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994;180:1263.
4. Van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol. 1997;9: 330-337.
5. Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol. 1999;11:203-210.
6. Chen LP. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4: 336-347.
7. Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-g production. Nat Immunol. 2001;2:269-274.
8. + cytolytic T cells. J Immunol. 2004;173: 5445-5450.
9. Sun X, Vale M, Leung E, et al. Mouse B7-H3 induces antitumor immunity. Gene Ther. 2003; 10:1728-1734.
10. Lupu CM, Eisenbach C, Lupu AD, et al. Adenoviral B7-H3 therapy induces tumor specific immune responses and reduces secondary metastasis in a murine model of colon cancer. Oncol Rep. 2007;18:745-748.
11. Ma L, Luo L, Qiao H, et al. Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J Hepatol. 2007; 46:98-106.
12. Lupu CM, Eisenbach C, Kuefner MA, et al. An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo. J Gastrointest Surg. 2006; 10:635-645.
13. Ling U, Wu PW, Spaulding V, et al. Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics. 2003;82:365-377.
14. Prasad Durbaka VR, Nguyen T, Zhaoxia L, et al. Murine B7-H3 is a negative regulator of T cells. J Immunol. 2004;173: 2500-2506.
15. Suh WK, Gajewska BU, Okada H, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. 2003;4: 899-906.
16. Roth TJ, Sheinin Y, Lohse CM, et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007;67:7893-7900.
17. Sun Y, Wang Y, Zhao J, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 2006;53: 143-151.
18. Xu J, Huang B, Xiong P, et al. Soluble mouse B7-H3 down-regulates dendritic cell stimulatory capacity to allogenic T cell proliferation and production of IL-2 and IFN-gamma. Cell Mol Immunol. 2006;3:235-240.
19. Steinberger PO, Majdic S, Derdak V, et al. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol. 2004;172: 2352-2359.
20. Albert ML, Sauter B, Bhardwaj N, et al. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392:86-89.
21. Albert ML, Pearce SF, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via αíβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 1998;188:1359-1368.
22. Gu T, Zhu YB, Chen C, et al. Fine-tuned expression of programmed death 1 ligands in mature dendritic cells stimulated by CD40 ligand is critical for the induction of an efficient tumor specific immune response. Cell Mol Immunol. 2008;5:33-39.
23. Sun M, Richards S, Prasad DV, et al. Characterization of mouse and human B7-H3 genes. J Immunol. 2002; 168:6294-6297.
24. Cella M, Scheidegger D, Palmer-Lehmann K, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996; 184:747-752.
25. Brendan JO, Thomas R. CD40 ligation conditions dendritic cell antigen-presenting function through sustained activation of NF-B. J Immunol. 2002;168:5491-5498.
26. Vissers JLM, Hartgers FC, Lindhout E, et al. BLC (CXCL13) is expressed by different dendritic cell subsets in vitro and in vivo. Eur J Immunol. 2001 ;31:1544-1549.
27. Kikuchi T, Moore MA, Crystal RG, et al. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood. 2000;96:91-99.